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ABSTRACT
Background: The inflammatory process has an important role in the pathophysiology of hepatic encephalopathy 
(HE) in liver cirrhosis. Interleukin-18 (IL-18) is a key mediator who plays a role in neuroinflamation processes 
that can lead to symptoms of HE. This study aimed to determine serum IL-18 levels in liver cirrhosis patients 
and to assess the association of serum IL-18 levels with HE. 
Method: A total of 52 subjects (32 patients with liver cirrhosis and 20 healthy controls) were enrolled in this 
study. Thirty two (32) patients with liver cirrhosis will be assessed for HE based on West-Haven criteria. All 
subjects were examined for serum IL-18 levels which is measured by ELISA method. We performed a comparative 
analysis between serum IL-18 levels of liver cirrhosis patients and healthy controls, a correlation analysis 
between serum IL-18 levels and HE, and a comparative analysis of serum IL-18 levels among degrees of HE.
Results: Mean serum IL-18 levels in the liver cirrhosis group were 688.5 ± 674.3 pg/mL, and in the healthy 
controls group were 163.9 ± 100 pg/mL with p = 0.01 (p < 0.05). There was a significant correlation between 
IL-18 and HE (r = 0.85; p = 0.00). Serum IL-18 levels in covert and overt HE groups were significantly higher 
than those without HE (p < 0.05).
Conclusion: Serum IL-18 levels were significantly higher in liver cirrhosis patients than in healthy controls. 
There was a positive correlation between IL-18 and HE. Serum IL-18 levels in liver cirrhosis patients with HE 
were significantly higher than those without HE.
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ABSTRAK
Latar belakang: Proses  inflamasi memiliki  peran  penting  dalam patofisiologi  terjadinya  ensefalopati 
hepatik (EH) pada sirosis hati. Interleukin-18 (IL-18) merupakan mediator kunci yang berperan dalam proses 
neuroinflamasi yang dapat menimbulkan gejala EH. Penelitian ini bertujuan mengetahui gambaran kadar IL-18 
serum pada pasien sirosis hati, menilai hubungan kadar IL-18 serum dengan EH dan menilai perbedaan kadar 
serum IL-18 antara pasien sirosis hati tanpa EH dan dengan EH.
Metode: Sebanyak 52 subjek (32 pasien sirosis hati dan 20 subjek sehat sebagai kontrol) terlibat dalam 
penelitian ini. Tiga puluh dua (32) pasien sirosis hati akan dinilai derajat EH berdasarkan kriteria West-Haven. 
Seluruh subjek penelitian diperiksa kadar IL-18 serum dengan metode ELISA. Dilakukan analisis perbandingan 
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antara kadar IL-18 serum pasien sirosis hati dengan subjek sehat, analisis korelasi antara kadar IL-18 serum 
dengan derajat EH, dan analisis perbandingan kadar serum IL-18 antara derajat EH.
Hasil: Rata-rata kadar IL-18 serum pada kelompok sirosis hati sebesar 688.5 ± 674.3 pg/mL, dan kelompok 
kontrol sehat sebesar 163.9 ± 100 pg/mL dengan nilai p sebesar 0.01 (p < 0.05). Hasil analisis korelasi antara 
kadar IL-18 serum dengan EH didapatkan koefisien korelasi sebesar 0.85 dengan nilai p sebesar 0.00 (p < 
0.05). Kadar serum IL-18 kelompok EH covert dan EH overt lebih tinggi dan berbeda bermakna dibandingkan 
dengan tanpa EH (p < 0.05)
Simpulan: Kadar IL-18 serum pada pasien sirosis hati lebih tinggi bila dibandingkan dengan subjek sehat, 
terdapat hubungan positif antara kadar IL-18 serum dengan EH pada pasien sirosis hati, dan kadar IL-18 serum 
pada pasien sirosis hati dengan EH lebih tinggi dibandingkan dengan tanpa EH.
Kata kunci: interleukin-18, sirosis hati, ensefalopati hepatik
INTRODUCTION
Hepatic encephalopathy (HE) is a neuropsychiatric 
syndrome associated with chronic and acute 
liver dysfunction, with clinical spectrum of 
neuropsychological disorders range from mild 
(subclinical) to coma.1 The prevalence rate of HE is 
quite high, in a mild/ subclinical clinical spectrum, the 
prevalence of HE ranging about 30-88% in patients 
with liver cirrhosis.2 Over the last 30 years, knowledge 
of HE has not changed much and seems to be largely 
ignored. This is seen with therapy that still aims to 
decrease the production of ammonia levels or increase 
its metabolism through the hepatic-urea cycle.3
The central role of ammonia in the pathogenesis 
of HE remains undeniable, but there has been some 
evidence that serum ammonia levels may be normal in 
30% of patients with overt HE,4 and serum ammonia 
levels may increase in 69% of patients without any HE 
signs and symptoms.5 This suggests that there are other 
factors in the pathogenesis of HE. The inflammatory 
process appears to be a key factor for HE, in addition 
to disturbed gastrointestinal tract disorders which 
lead to microbiota dysbiosis, overgrowth of bacteria, 
bacterial translocation, systemic endotoxaemia and 
immune dysfunction.1 Shawcross shows that patients 
with liver cirrhosis with hyperamonia due to amino 
acid oral administration to sepsis conditions, there are 
increases in proinflammatory mediators such as TNF-α, 
IL-1β and IL-6, and poor neuropsychiatric examination 
results. This is different than patients with hyperamonia 
without an inflammatory condition.7 This suggests that 
hyperamonia alone is not enough to make patients with 
liver cirrhosis fall into HE.
One of  the  key media tors  involved in 
neuroinflammatory processes is IL-18.8 The IL-18 
bond with its receptors in the central nervous system in 
addition to their role in neuroinflammatory processes 
may also affect individual behavior, as occurs in liver 
cirrhosis patients with HE.9 Ludwiczek et al shows 
significant plasma IL-18 level increase in patients with 
liver cirrhosis compared with healthy controls. The IL-
18 plasma level increases in parallel with the progression 
of liver cirrhosis.10 However, its relationship to the stage 
of HE has not been clearly defined. In Indonesia alone, 
no study have shown correlation between serum levels 
of IL-18 and HE, therefore this study aims to know 
the serum IL-18 level in liver cirrhosis patients, assess 
the association of serum IL-18 with HE and assess 
the difference in serum IL- 18 between liver cirrhosis 
patients without HE and with HE.
METHOD
This study was cross-sectional observational. The 
population of this study were all patients of liver 
cirrhosis in Dr. Saiful Anwar General Hospital, Malang. 
The sample of this study was liver cirrhosis patients 
who had excluded and met inclusion criteria. Patients 
are given an explanation of the intent and purpose of the 
study, then asked to sign an informed consent if they are 
willing to take part in the study. Technique of sampling 
by consecutive sampling. The inclusion criteria of this 
study include: (1) Male or female patients aged 18-
79 years; (2) Liver cirrhosis patients with or without 
hepatic encephalopathy. Exclusion criteria for the study 
included: (1) Patients with hepatocellular carcinoma; 
(2) Liver cirrhosis patients with stroke and its sequelae; 
(3) Hypoglycemia.
The healthy subjects will be used as controls to 
compare serum IL-18 levels in healthy subjects and 
patients with liver cirrhosis. The healthy subjects 
will be matched by age and gender with liver 
cirrhosis patients. Subjects said to be healthy after 
anamnesis, physical examination and laboratory test 
showed normal results. Blood samples were taken by 
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phlebotomy of venous blood as much as 3 mL and 
inserted into vacutainer tube without ethylene diamine 
tetra acetate. The blood is centrifuged for 10 minutes 
to obtain serum. The obtained serum is stored at -80 
°C until it is used for enzyme-linked immunosorbent 
assay (ELISA) examination. IL-18 examination using 
ELISA rapid with Human IL-18 serum Elabscience kit.
This study was conducted between May 2017 and 
October 2017 in Gastroentero-hepatology Polyclinic, 
Internal Medicine inpatient ward, Dr. Saiful Anwar 
General Hospital Malang, and Biomedical Laboratory, 
Faculty of Medicine, Universitas Brawijaya Malang.
Statistical analysis with numerical comparative 
tests will be used to see differences between serum IL-
18 levels in cirrhotic patients with healthy control and 
to determine the ratio of serum IL-18 levels between 
groups of HE stages. The correlation test will be used 
to analyze the association of serum IL-18 levels with 
hepatic encephalopathy. Statistical analysis of data 
using statistical products and service solutions (SPSS) 
program statistics, version 17 for windows.
RESULTS
There were 52 subjects were enrolled during this 
study that consist of 32 patients with liver cirrhosis 
and 20 people as healthy control. We had performed 
HE assessment to 32 cirrhotic patients based on the 
West Haven criteria. It was obtained that 6 patients 
without symptoms of HE; 5 patients with minimal HE; 
6 patients with stage 1 HE; 3 patients with stage 2 HE; 
8 patients with stage 3 HE; and 4 patients with stage 4 
HE. Characteristics of subjects are shown in Table 1.
Table 1. Characteristics of liver cirrhotic patients and healthy 
controls
Characteristics
Group
pLiver cirrhosis  
(n = 32)
Control  
(n = 20)
Sex 0.45
 Male 24 (75%) 13 (65%)
 Female 8 (25%) 7 (35%)
Age 49.5 ± 8.2 48.4 ± 12 0.70
Cause of liver 
Cirrhosis
 Hepatitis B 19 (59.4%) - -
 Hepatitis C 8 (25%) - -
 Non-B Non-C 5 (15.6%) - -
Stage of hepatic encephalopathy (HE)
 Without HE 6 (18.8%) - -
 Minimal HE 5 (15.6%) - -
 Stage 1 6 (18.8%) - -
 Stage 2 3 (9.4%) - -
 Stage 3 8 (25%) - -
 Stage 4 4 (12.5%) - -
Child-turcotte-
pugh (CTP)
 A 8 (25%) - -
 B 5 (15.6%) - -
 C 19 (59.4%) - -
Characteristics
Group
pLiver cirrhosis  
(n = 32)
Control  
(n = 20)
Hb (mg/dL) 9.8 ± 2.2 14.1 ± 0.5 0.00*
Leukosit (/μL) 11211.9 ± 7486 7538 ± 1405.5 0.14
Trombosit (/μL) 98000 ± 40452.3 342350 ± 79898.1 0.00*
AST (U/L) 55.8 ± 27.4 20.2 ± 7.5 0.00*
ALT (U/L) 39.6 ± 18.4 20.1 ± 12.3 0.00*
Ureum (mg/dL) 76.2 ± 69.5 29.8 ± 1.6 0.01*
Creatinin (mg/dL) 1.8 ± 1.9 0.8 ± 0.1 0.04*
Natrium (mmol/L) 128.1 ± 7.8 140 ± 3.5 0.00*
Kalium (mmol/L) 4.5 ± 1 3.9 ± 0.3 0.08
Cloride (mmol/L) 102.8 ± 7.7 98 ± 1.7 0.00*
Random blood 
glucose (mg/dL)
128.9 ± 26.3 103 ± 16 0.06
*statistically significant (p < 0.05) with Mann-Whitney test; Hb: hemoglobin; 
AST: aspartate aminotransferase; ALT: alanine aminotransferase
Serum IL-18 test results between the liver cirrhosis 
group and healthy control group can be seen in Figure 2.
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test, p value is 0.01 (p < 0.05). It was proved that the mean serum IL-18 levels in the liver 
Me
an
 of
 se
rum
 IL
-18
 le
ve
ls 
Control Liver cirrhosis
Figure 2. Differences in serum IL-18 levels between liver 
cirrhosis group and healthy control group.
Figure 2 shows that the mean serum IL-18 levels 
in the liver cirrhosis group were 688.5 ± 674.3 pg/mL, 
and the healthy control group of 163.9 ± 100 pg/mL. 
By using Mann-Whitney test, p is 0.01 (p < 0.05). It 
was proved that the mean serum IL-18 levels in the 
liver cirrhosis group were higher and significantly 
different with the healthy control group. The results of 
this analysis prove that there is elevated serum IL-18 
level in patients with liver cirrhosis.
Table 2. Serum IL-18 levels of liver cirrhosis patients with 
various degrees of hepatic encephalopathy
Stage of hepatic encephalopathy Mean serum IL-18 levels  (pg/mL)
Without hepatic encephalopathy (HE) 81.37 ± 47.68
Minimal hepatic encephalopathy (HE) 155.42 ± 103.35
Stage 1 354.02 ± 297.83
Stage 2 804.83 ± 561.61
Stage 3 1200 ± 629
Stage 4 1656.75 ± 33.75
From Table 2, the lowest average serum IL-18 
levels were found in liver cirrhosis patients without 
HE, and this value continued to increase to the highest 
level in liver cirrhosis patients with a stage 4 HE. The 
results of analysis of correlation between serum IL-18 
levels and HE in liver cirrhosis patients, it was obtained 
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correlation coefficient of 0.85 with p = 0.00 (p < 0.05). 
It was shown that there was a significant relationship 
between serum IL-18 levels and HE in liver cirrhosis 
patients. The correlation coefficient of 0.85 indicates a 
very strong association between serum IL-18 levels and 
HE in liver cirrhosis patients. The positive correlation 
coefficient indicates that elevated serum IL-18 levels 
will be followed by elevated HE degree, and vice versa. 
Correlation of serum IL-18 levels with HE levels in 
patients with liver cirrhosis is shown in Figure 3.
was obtained p-value of 0.247 (p > 0.05) showed no 
significant difference. While compared to the groups 
of patients at 1-4 degrees, p was less than 0.05 (p < 
0.05) indicating a significant increase in IL-18 levels.
Based on severity of symptom, HE can be divided 
into 2 groups ie covert HE (minimum HE and stage 1 
HE) and overt HE (stage 2, 3 and 4 HE). To determine 
the difference of IL-18 levels between the groups, 
Kruskal-Wallis test and Mann-Whitney test were 
performed. The test results of different serum IL-18 
levels based on the each stage HE group in liver 
cirrhosis patients are shown in Figure 5.
Figure 3. Correlation of serum IL-18 levels with hepatic 
encephalopathy (HE) degree in liver cirrhosis patients
Difference in test results of serum IL-18 levels 
based on the degree of HE in patients with liver 
cirrhosis are shown in Figure 4.
Figure 5. Differences in serum IL-18 levels between hepatic 
encephalopathy (HE) groups in liver cirrhosis patients. 
Description = The red line shows the value of p < 0.05
Based on Figure 5, there was a significant difference 
in serum IL-18 levels between group without HE and 
with covert HE (p = 0.03), group without HE with overt 
HE (p = 0.00), and covert HE with overt HE (p = 0.00).
DISCUSSION
Of the 32 patients with liver cirrhosis who were the 
subject of the study, 75% of the patients were male and 
25% were female. In southern China, Xing Wang et al 
reported that most liver cirrhosis patients were men of 
83.16% and 16.84% were female.11 The study, carried 
out by Tambunan et al in Dr. Soedarso Pontianak 
during period January 2008 - December 2010 which 
also get the largest patient of cirrhosis hepatis is male 
equal to 69,6%.12 The same thing reported by Dr. M. 
Djamil Padang General Hospital which in patients with 
liver cirrhosis, the percentage of male (65.8%) more 
than female.13 Gender is thought to have a role in the 
occurrence of cirrhosis hepatis, men have different 
social environment and lifestyle than women, men 
generally have a greater chance of contact with viral 
With the Mann-Whitney test, the difference in 
serum IL-18 levels in the liver cirrhosis patients 
between without HE and with minimum HE group, it 
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hepatitis and alcohol consumption.14 The median age of 
patients with liver cirrhosis in this study was 49.5 ± 8.2 
years. This is in accordance with the literature which 
states that the average age of sufferers most age group 
30-59 years with peak around the age of 40-49 years.15 
In our study, the most common cause of liver 
cirrhosis was hepatitis B virus infection of 59.4% 
followed by hepatitis C of 25%. In developed countries, 
the most common causes of liver cirrhosis are alcoholic 
liver disease and hepatitis C virus infection, whereas in 
Southeast Asia, the main causes of liver cirrhosis are 
hepatitis B and hepatitis C virus infection.15,16 
From the results of this study, 18.8% (6 patients) 
had no symptoms of hepatic encephalopathy while 
81.2% (26 patients) were accompanied by hepatic 
encephalopathy. Based on West Haven criteria, from 26 
patients; 5 patients (15.6%) were found with minimal 
HE; 6 patients (18.8%) with stage 1 HE; 3 patients 
(9.4%) with stage 2 HE; 8 patients (25%) with stage 
3 HE; and 4 patients (12.5%) with stage 4 degree HE. 
Thus, the outline of this study indicates that 34.3% 
of patients belong to covert HE and 47% of patients 
belong to overt HE. These findings are consistent with 
the literature which stated that HE prevalence in a mild/ 
subclinical clinical spectrum varies between 30-88% in 
patients with liver cirrhosis, whereas overt HE occurs 
in about 45% of patients with liver cirrhosis.2,17
A total of 20 healthy subjects participated as 
controls in this study, including 7 women and 13 men 
with an average age of 48.4 ± 12 years. From the test 
results, the difference between liver cirrhosis group 
and control of gender characteristics and age was 
found p greater than 0.05 (p > 0.05) indicating that 
both groups had uniform or homogeneous gender and 
age characteristics. The uniformity of sex and age 
in this study is important because based on research 
conducted by Ferrucci et al showed that IL-18 levels 
differ by sex and age group.18 
From the analysis, it was proved that the mean 
serum IL-18 levels in the liver cirrhosis group were 
higher and significantly different than the healthy 
control group. This is consistent with Ludwiczek et 
al’s study which suggested that there is a significant 
difference in plasma IL-18 levels in liver cirrhosis 
patients when compared with healthy controls.10
The results of this study indicate that there is an 
elevated serum IL-18 level in patients with liver 
cirrhosis. The high serum IL-18 concentration 
was associated with elevated plasma endotoxin or 
Lipopolysaccharide (LPS) levels of the gastrointestinal 
microbiota in liver cirrhosis patients.19 Hanck et al 
demonstrated a significant increase in plasma LPS 
levels in liver cirrhosis patients when compared with 
healthy controls.19 LPS plasma levels is also associated 
with increased expression of IL-18 genes by peripheral 
blood mononuclear cells.19 In vitro study also showed 
that LPS stimulates expression of IL-18 by peripheral 
blood mononuclear cells.20 
In addition to increased IL-18 expression by 
peripheral blood mononuclear cells due to LPS 
stimulation, high serum IL-18 levels in patients with 
liver cirrhosis reflect liver clearance failure on LPS 
caused by portosystemic shortcuts, phagocyte capacity 
defect of the liver reticuloendothelial system and 
decreased endotoxin binding capacity.19,21
This study has proved that there is a very strong 
association between serum IL-18 levels and hepatic 
encephalopathy in patients with liver cirrhosis with 
a positive correlation coefficient indicating elevated 
serum IL-18 levels will be followed by elevated 
HE stage. This is consistent with the Jain et al study 
which also showed a significant association between 
serum IL-18 levels and hepatic encephalopathy (r = 
0.76; p = 0.02).21 In addition to IL-18, Jain et al also 
proved a positive correlation between proinflammatory 
cytokines (TNF-α, IL-6), endotoxin serum with hepatic 
encephalopathy stage.22 
This study shows that there is role of inflammation 
in the pathophysiology of hepatic encephalopathy 
in patients with liver cirrhosis. The underlying 
mechanisms of IL-18 in the pathophysiology of hepatic 
encephalopathy are evidenced by in vitro study of 
laboratory animals (rat) demonstrating that IL-18 
destroys long-term potentiation and signal transduction 
mediated by N-methyl D-aspartate-receptor in the 
hippocampus.23 Both processes are involved in learning 
and memory formation. This suggests that IL-18 may 
also cause changes that lead to decreased cognitive 
function.24
This study proves that IL-18 can differentiate 
between cirrhosis of the liver without hepatic 
encephalopathy, with covert and overt encephalopathy 
hepatic. Similarly, study conducted by Montoliu et al 
also demonstrated that significantly higher IL-18 levels 
in patients with liver cirrhosis with a minimum HE 
when compared with liver cirrhosis without HE.24 IL-
18 may be a good indicator for detecting covert HE.24 
This study has shown that there is a role of 
inflammation in the pathophysiology of hepatic 
encephalopathy in patients with liver cirrhosis. The 
clinical consequence of the role of inflammation in 
the pathophysiology of hepatic encephalopathy is in 
The Indonesian Journal of Gastroenterology, Hepatology and Digestive Endoscopy72
Anton Komala, Syifa Mustika, Bogi Pratomo
its treatment. Cauli et al in his study provided non-
steroidal anti-inflammatory drug (NSAID) ibuprofen in 
rat-experimental animals with hepatic encephalopathy 
and resulted in decreased neuroinflammation and 
improved cognitive and motor abilities.25 However, 
NSAID administration may induce gastropathy, and 
have secondary effects on damage kidney, so that 
other therapeutic modalities are required which able 
to eliminate neuroinflammation in patients with liver 
cirrhosis with hepatic encephalopathy.26,27
IL-18 is a potent protein kinase activator p38 
mitogen-activated protein kinase (MAPK).27 p38 
MAPK is the meeting point of various signaling 
processes involved in inflammation. The activity of 
p38 increases in the brain cortex of mouse-fed animals 
with hepatic encephalopathy.28,29 The role of p38 in 
inflammation and neuroinflammation makes it an 
attractive target for novel therapy.29
The limitation of this study is the number of 
samples lacking to test the diagnostic value of IL-18 
in differentiating patients with liver cirrhosis without 
hepatic encephalopathy and with covert hepatic 
encephalopathy. In addition, this study did not observe 
changes in serum IL-18 levels when improving the 
symptoms of HE after patients received treatment.
CONCLUSION
From the results and analysis of the research, 
it can be concluded that serum IL-18 levels were 
significantly higher in liver cirrhosis patients than 
in healthy controls. There was a positive correlation 
between IL-18 and HE in liver cirrhosis patients and 
serum IL-18 levels in liver cirrhosis patients with HE 
were significantly higher than those without HE.
Further research with a larger sample is needed to 
test the serum IL-18 diagnostic value in distinguishing 
liver cirrhosis patients without hepatic encephalopathy 
and with covert hepatic encephalopathy. Serum IL-
18 should be required after improvement of hepatic 
encephalopathy symptoms which will support IL-18 
correlation with hepatic encephalopathy degree.
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